Please assess the completion status of the following clinical trial:

Trial Title: Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~* Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed~* Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period~* Subjects must be deemed by the investigator to benefit from continued secukinumab therapy~Exclusion criteria~* Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab~* Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms~* Pregnant or nursing (lactating) women~* Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 75mg (Type: EXPERIMENTAL): Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
- Secukinumab 150mg (Type: EXPERIMENTAL): Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
- Placebo - AIN457A 75mg (Type: EXPERIMENTAL): Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
- Placebo - AIN457 150mg (Type: EXPERIMENTAL): Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).